Evolution Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Evolution Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-116	Closed	-$9K	–	218
2021 Q3	$9K	Sell	116 -177	-60%	-$14K	﹤0.01%	407
2021 Q2	$24K	Hold	293	–	–	﹤0.01%	284
2021 Q1	$22K	Sell	293 -88	-23%	-$7.19K	﹤0.01%	279
2020 Q4	$33K	Buy	381 +43	+13%	+$3.41K	0.01%	211
2020 Q3	$26K	Buy	338 +20	+6%	+$2.02K	0.01%	243
2020 Q2	$39K	Buy	318 +92	+41%	+$9.14K	0.01%	155
2020 Q1	$19K	Buy	+226	New	+$19.5K	0.01%	155

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Evolution Wealth Advisors's BMRN Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 116 shares — an estimated $9K sold.

Evolution Wealth Advisors first reported a position in BMRN in Q1 2020 and held it in 7 quarters. The position peaked at $39K in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Evolution Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 116 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $9K.
Evolution Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 7 quarters.
Evolution Wealth Advisors's BioMarin Pharmaceuticals position peaked at $39K in Q2 2020.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.